(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Pleasant Cycle Courses All over the Planet- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- An Ideal Getaway - Spots for Solo Travel
- 5 Morning Schedules That Stimulate Your Day
- Vote In favor of Your Favored Sort Of Bevarage
- Figure out How to Use Your Nursing Abilities for Better Compensation
- Most loved Web-based feature: Which Stage Do You Like
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
